PCM
VRDN icon

Prelude Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Prelude Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,401
Closed -$243K – 1406
2025
Q2 		$243K Sell
17,401
-50,268
-74% -$682K 0.02% 712
2025
Q1 		$912K Buy
+67,669
New +$1.15M 0.07% 332
2024
Q4 		– Sell
-51,050
Closed -$1.16M – 1588
2024
Q3 		$1.16M Buy
+51,050
New +$835K 0.07% 344
2018
Q3 		– Sell
-400
Closed -$38K – 2058
2018
Q2 		$38K Buy
400
+67
+20% +$7.08K ﹤0.01% 1196
2018
Q1 		$35K Buy
333
+66
+25% +$7.17K ﹤0.01% 1170
2017
Q4 		$42K Sell
267
-166
-38% -$21.1K ﹤0.01% 970
2017
Q3 		$59K Buy
433
+42
+11% +$7.06K 0.01% 1049
2017
Q2 		$76K Buy
391
+47
+14% +$7.93K 0.01% 867
2017
Q1 		$64K Buy
344
+177
+106% +$30.5K 0.01% 910
2016
Q4 		$13K Buy
+167
New +$17.4K ﹤0.01% 1357

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Prelude Capital Management's VRDN Position: Q3 2025 in Review

Prelude Capital Management sold out of Viridian Therapeutics (VRDN) in Q3 2025, closing a stake of 17,401 shares — an estimated $243K sold.

Prelude Capital Management first reported a position in VRDN in Q4 2016 and held it in 10 quarters. The position peaked at $1.16M in Q3 2024. 169 funds tracked by Wall St. Rank hold VRDN as of Q3 2025.

  • Prelude Capital Management reported no remaining Viridian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 17,401 Viridian Therapeutics shares in Q3 2025, an estimated $243K.
  • Prelude Capital Management first reported a position in Viridian Therapeutics in Q4 2016 and held it in 10 quarters.
  • Prelude Capital Management's Viridian Therapeutics position peaked at $1.16M in Q3 2024.
  • 169 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.